The Next Generation B2 Receptor Antagonist

Jerini has leading expertise in the pathophysiology of bradykinin and has established the utility and efficacy of bradykinin B2 receptor antagonists in clinical trials with the peptidomimetic Icatibant. Since a pathophysiological level of bradykinin is associated with a variety of disease conditions, both chronic and acute, Jerini has begun the development of JSM 10292 an orally-available small molecule bradykinin B2 receptor antagonist compound. At this time, the company has identified small molecules showing high activity and good oral bioavailability.

The German Federal Ministry for Education and Research is supporting this project with grant funding.

Top